Sudeep Pharma’s Rs 895-crore IPO enters its final bidding day with strong overall demand, led by robust NII and retail participation. Despite a softening grey-market premium, subscription momentum remains healthy. Backed by diversified excipient capabilities, steady financial growth and anchor interest, the company is positioned favourably as it approaches allotment and listing.
Sudeep Pharma IPO final day: GMP falls, issue gets strong subscription. Should you apply?
📅 Published: November 25, 2025 |
📂 Category: Uncategorized